0
Letters |

Lipoprotein(a) Measurement and Determining Risk of Myocardial Infarction

Steven R. Jones, MD; Roger S. Blumenthal, MD
JAMA. 2009;302(15):1645-1646. doi:10.1001/jama.2009.1483.
Text Size: A A A
Published online

Extract

To the Editor: Dr Kamstrup and colleagues1 assessed the association between elevated lipoprotein(a) and risk of myocardial infarction using data from the Copenhagen General Population Study (CGPS), the Copenhagen City Heart Study, and the Copenhagen Ischemic Heart Disease Study. We believe that several limitations were not adequately addressed in their article.

Measurement of lipoprotein(a) levels in the CGPS began before the IFCC/WHO consensus on lipoprotein(a) and the SRM-2B reference reagent study2 leading to adoption of lipoprotein(a) measurement as a molar particle concentration (lipoprotein[a]-P), independent of apolipoprotein(a) kringle IV type 2 repeat isoform. The values of lipoprotein(a) in the CGPS are based on an assay determining lipoprotein(a) mass and are subject to bias by apolipoprotein(a) molecular weight. Comparison with current isoform-independent molar assays confirms substantial bias with the older methods.2 The generalizability of the CGPS lipoprotein(a) serum level and lipoprotein(a) population percentile data to current lipoprotein(a) molar serum assays may be limited by the differences in measurement methodology.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

October 21, 2009
Pia R. Kamstrup, MD, PhD; Børge G. Nordestgaard, MD, DMSc
JAMA. 2009;302(15):1645-1646. doi:10.1001/jama.2009.1484.
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs